Back to search results

TRIBECA Study: Easier Cataract Surgery Recovery

This study, called TRIBECA, is looking at new ways to manage pain and inflammation after cataract surgery. It compares two different treatment plans that use fewer eye drops to a traditional plan that requires more drops. You would receive either a subconjunctival injection of triamcinolone (Triesence) or topical clobetasol (Byqlovi) eye drops, along with other medications like nepafenac (Ilevro) and moxifloxacin. The study wants to see if these new approaches are safe, work well, and are easier for patients to use. You can join if you are over 22 years old and in good general health, and will be having cataract surgery in both eyes. The main goal is to see how well these treatments control pain and inflammation 14 days after surgery in each eye. The current status of the study is unclear.

Study design
This is a self-controlled study where one eye receives a standard treatment and the other eye receives a new treatment. It plans to enroll 40 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be checked 14 days after cataract surgery in each eye.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07276802

The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

Not Yet Recruiting
PHASE4Ages 22+InterventionalPrevention
Research Insight LLC
~40 participants
Updated 2026-03-31 on ClinicalTrials.gov
What's tested:Triamcinolone (Optional)control group

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary
Measured over 14 days after cataract surgery in each eye
+1 more outcome measured

Conditions

Post Cataract Surgery

Explore related trials

Cataract

Where it's being run

1 sites across 1 states
California1

Who to contact

John Hovanesian, MD
[email protected]
949-951-2020
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A male or female subject in good general health, \> 22 years of age at the time of the screening visit
A subject must be able to comprehend and willing to give informed consent
A woman of child-bearing potential must not be pregnant or lactating.
A subject has the availability, willingness and sufficient cognitive awareness to comply with exam procedures and able to return for all scheduled study visits
A subject with a cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned
A subject with clear ocular media other than cataract in their scheduled operative eye
A subject with normal OCT of the macula in both eyes
A subject has the potential for a post-operative Snellen BCDVA of 20/30 or better in both eyes

Exclusion

A subject with a history of complications, adverse events, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye
A subject with any moderate to severe lid, conjunctival or corneal findings in either eye at the screening visit
A subject with any signs of intraocular inflammation (cells/flare) in either eye at the screening visit
A subject with a known sensitivity to any of the study medications.
A subject with a history as a steroid responder or glaucoma
A subject with a known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article
A subject with only one eye with potentially good vision
A subject with a known pathology that may affect visual acuity (as determined by the Investigator); particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.) in their scheduled surgical eye
A subject that has a condition associated with the fluctuation of hormones that could lead to refractive changes
A subject with amblyopia or strabismus
A subject has a history of ocular trauma in their scheduled surgical eye
A subject that has undergone prior intraocular surgery in the scheduled surgical eye within the last 6 months or laser surgery within three months prior to screening
A subject with pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions) in their scheduled surgical eye.
A subject with a clinically significant corneal abnormality (e.g., stromal, epithelial or endothelial dystrophies) that, in the best judgment of the investigator, is likely to interfere with the outcomes of the study
A subject with an inability to achieve keratometric stability for contact lens wearers
A subject with a history of chronic/recurrent inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis) in either eye
A subject with uncontrolled glaucoma
A subject that requires the use of systemic or ocular medications that may affect vision, ocular inflammation or pain
A subject with an acute or chronic disease, or illness, that would increase risk or confound study results (e.g., autoimmune disease, connective tissue disease, immunocompromised, suspected glaucoma, glaucomatous changes in the fundus or visual field, other source of ocular inflammation, etc.)
A subject with an uncontrolled systemic disease: A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study
A subject with diabetes that is poorly controlled
A subject currently participating or has participated in another clinical trial within 30 days prior to enrollment.
Sulcus-sulcus or bag-sulcus fixation
Posterior capsular rupture or zonular dialysis
Disruption of anterior hyaloid face
Vitreous loss
Floppy iris syndrome
Inability to place IOL in capsular bag
Significant anterior chamber hyphema
Significant zonular rupture.

What this trial measures

  • Primary14 days after cataract surgery in each eye

    Patient Preference Between Medication Protocols (COMTOL Questionnaire Question 1)

  • Primary14 days after cataract surgery in each eye

    Patient preference for medication protocol between the two eyes, as reported based on the question, "Thinking about your overall experience taking medications in each eye after surgery, which eye did you prefer?" (question 1 from validated COMTOL questionnaire)